The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 11, 2026

Filed:

Jan. 30, 2024
Applicant:

The Research Foundation for the State University of New York, Albany, NY (US);

Inventors:

Juntao Luo, Syracuse, NY (US);

Xiaotian Ji, Syracuse, NY (US);

Changying Shi, Syracuse, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/51 (2006.01); A61K 31/7048 (2006.01); A61P 31/10 (2006.01); B82Y 5/00 (2011.01);
U.S. Cl.
CPC ...
A61K 9/5146 (2013.01); A61K 9/5192 (2013.01); A61K 31/7048 (2013.01); A61P 31/10 (2018.01); B82Y 5/00 (2013.01);
Abstract

Systemic fungal infections are an increasingly prevalent health problem. Amphotericin B (AmB), a hydrophobic polyene antibiotic, remains the drug of choice for life-threatening invasive fungal infections. Embodiments disclosed herein are directed telodendrimer (TD) nanocarriers having freely engineered core structures for AmB encapsulation to reduce AmB aggregation status. The reduced aggregation status correlates with the optimized antifungal activity and the attenuated hemolytic properties, as well as reduced cytotoxicity to mammalian cells. The disclosed optimized TD nanocarrier for monomeric AmB encapsulation significantly increases the therapeutic index and reduces the in vivo toxicity and enhances antifungal effects in mouse models withinfection in comparison to two common clinical formulations, i.e., Fungizone and AmBisome.


Find Patent Forward Citations

Loading…